咪唑钴啉酯的合成及钴-氮键稳定性的研究

合成了维生素B~1~2(VB~1~2)模型分子-单腈N-甲基3-咪唑基钴啉酯高氯酸盐8。通过8在不同pH缓冲溶液中的UV-Vis谱,计算了Co-N键的平衡常数,独立配位体N-甲基咪唑与咕啉环中心钴原子配位键的键强与自身键连配位体的配位键强要弱。     

维生素B12模型分子侧链钴-氮键稳定性研究

维生素B12(VB12)模型分子[单腈六甲基-N-(3-咪唑基)丙酰胺钴啉酯高氯酸盐4b-4f],在甲醇溶液中用酸性缓冲溶液处理生成5b-5f.通过测定不同pH的缓冲溶液中的UV-Vis谱,计算了Co-N键的平衡常数,侧链氮原子与中心钴离子配位键的强弱次序为4d＞4f＞4c＞4e＞4b.     

乳酸钴配合物与牛血清蛋白相互作用的研究

合成和表征了系列乳酸钴配合物,测定二水二乳酸钴配合物的结构,配合物中乳酸的羟基和羧基配位键平均键长分别为0.206 0(2)nm和0.206 8(2)nm。当[Co(Hlact)2(H2O)2](2)或[Co(Hlact)2(phen)].2H2O(4)配合物与牛血清白蛋白(BSA=Bovine SerumAlbumin)相互作用后,红外光谱显示乳酸或邻菲咯啉的特征吸收消失,钴离子与BSA出现新的配位,初步推定乳酸或邻菲咯啉配体被BSA中的强配体所取代。     

N-(4-乙烯基)苄基咪唑共聚物的合成及与钴卟啉络合物的氧结合性能

研究了N-(4-乙烯基)苄基咪唑单体及其与甲基丙烯酸辛酯共聚物(PBIOM)的合成与表征,以及咪唑基有机或聚合物配位体与钴卟啉(CoP)络合物的氧结合性能.合成的PBIOM重均分子量和咪唑基含量分别由GPC和元素分析方法测定,结果为3.4×105和57 mol%.PBIOM或苄基咪唑(BIm)中的咪唑基与CoP在溶液中配位,得到的CoP-PBIOM或CoP-BIm络合物具有快速、可逆的氧结合特性.相同氧气分压下CoP-BIm络合物在三氯甲烷溶液中的氧结合百分率略大于CoP-PBIOM络合物.CoP-PBIOM络合物固体膜的氧结合亲和力大于三氯甲烷溶液中的氧结合亲和力.60℃下CoP-PBIOM固体膜的氧结合半衰期为40.7 h,而CoP-BIm固体膜为8.8 h,表明聚合物配位体显著提高了CoP络合物的氧结合寿命.     

1,2-二甲基咪唑啉的合成及表征

对1,2-二甲基咪唑啉的合成进行了详细研究. 以甲胺水溶液和2-溴乙胺氢溴酸盐(1)为原料进行反应, 在两种原料物质的量之比为5∶1, 缓缓回流12 h的条件下, 得到N-甲基乙二胺(2), N-甲基乙二胺经过乙酸化得到N-甲基-N,N′-二乙酰基乙二胺(3), 然后, N-甲基-N,N′-二乙酰基乙二胺和氧化钙在高温下关环得到1,2-二甲基咪唑啉(4). 并对所得到的产物1,2-二甲基咪唑啉经元素分析, 1H NMR, IR和GC-MS得到了表征.     

维生素B12模型分子侧链钴—氮键稳定性研究

维生素Ｂ１２模型分子「单腈六甲基－Ｎ－（３－咪唑在）丙酰胺钴啉酯高氯酸盐４ｂ－４ｆ」，在甲醇溶液中用酸性缓冲溶液处理生成５ｂ－５ｆ。通过测定不同ＰＨ的缓冲溶液中的ＵＶ－Ｖｉｓ谱。，计算了Ｃｏ－Ｎ键的平衡常数，侧链氮原子与中心钴离子配位键的强弱次序为４ｄ－４ｆ－４ｃ－４ｅ－４ｄ。     

离聚体的结构表征 Ⅲ.EXAFS法测定含氟的铜离聚体的精细结构

本文报道了用先进的EXAFS及ESR等方法研究了羧酸型含氟的铜(Ⅱ)离聚体离子微区的内部精细结构,结果表明,铜离聚体的离子微区主要由羧酸根桥键的双核配位结构单元及平面四方形的配位结构单元等聚集而成。在双核配位结构单元中第一层为Cu~(2+)—O配位,配位数为4,配位键键长为1.96A,第二配位层为Gu~(2+)—Cu~(2+)配位,Cu~(2+)—Gu~(2+)间距为2.64A。平面四方形的配位结构单元Cu~(2+)—O的配位数为4,配位键键长为1.96A。共聚物中羧基含量对离聚体的基本配位结构单元和离子微区的精细结构影响较小,但对微区大小有影响。     

双分子维生素B_(12)模型分子的合成及表征

维生素B_(12)经醇解得到的七甲基钴啉酯1作为起始原料，经酸性水解分别得 到b,c,d,e,f-单酸钴啉酯2b～2f, 2b～2f与3-咪唑基丙胺盐酸盐反应合成了相应的 酰胺钴啉酯衍生物3b～3f, 3b～3f在乙酸的作用下合成了双分子络合维生素B_(12) 模型化合物双-单腈六甲基-N-（3-咪唑基）丙酰胺钴啉酯高氯酸盐5b～5f，并对其 化学结构进行了表征。     

双分子维生素B12模型分子的合成及钴氮键稳定性研究

在合成单分子 B12 模型分子β-单腈 a,b,c,d,e,g-六甲基 -α- f- N - (3 -咪唑基 )丙酰胺钴啉酯高氯酸盐4f的基础上 [1～ 3 ] ,合成了双分子维生素 B12 模型分子 [4 ] ,为研究 B12 化学提供了一类新型的模型分子 ,并研究了 Co— N键的稳定性 .1　实验部分1 .1　仪器及原料　 Pe     

GFP生色团衍生物的合成及其荧光性能

以N-甲基乙酰胺或N-甲基苯甲酰胺为起始原料,与氯乙酰氯经酰化反应后,与叠氮钠经取代反应制得二酰亚胺(2); 2在三苯基膦的催化下发生分子内氮杂Witting反应制得关键中间体--咪唑啉酮(3); 3与芳醛在碱性条件下经缩合反应合成了8个新型的GFP生色团衍生物(5a~5h),其结构经¹H NMR和¹³C NMR表征。对5a~5h的激发波长和发射波长进行了研究。结果表明,与对羟基苯咪唑啉酮(p-HOBDI)相比,大部分化合物的发射波长发生了比较显著的红移,其中2-羟基5-硝基苯咪唑啉酮(5f)的发射波长达614 nm。     

丙二胺缩乙酰丙酮单席夫碱、咪唑金属配合物的XPS与电子结构分析

对6个丙二胺缩乙酰丙酮单席夫碱、咪唑（苯并咪唑）金属配合物进行了XPS分析，得到了配合物在生成过程中金属离子M(Cu^2 、Ni^2 、Co^2 ）的2p轨道、配位体N原子的1s轨道能级的变化道；观察到咪唑或苯并咪唑配位后，其环上另一个非配位的胺N原子向亚胺型N原子状态过渡。     

3-硝基苯乙酮缩氨基硫脲合铜、锌、钴、镍配合物和抑菌活性Ⅰ

３－硝基苯乙酮缩氨基硫脲合铜、锌、钴、镍配合物和抑菌活性Ⅰ刘建宁（庆阳师专化学系西峰７４５０００）赵建设任友贤（西北大学化学系西安７１００６９）关键词３－硝基苯乙酮缩氨基硫脲过渡金属配合物抑菌活性中图分类Ｏ６４１．４自Ｄｏｍａｇｋ发现缩氨基硫脲类化合...     

Large 1,3,5-triazine-based ligands coordinating transition metal ions: syntheses and structures of the ligands and the ball shaped nanometer-scaled Co complex [Co(2,4-R-6-R′-1,3,5-triazine)2](Br1.7(OH)0.3) · 4.8H2O {R = bis(2-diphenylmethylene) hydrazinyl; R′ = piperidin-1-yl}

Two new, large 1,3,5-triazine-based ligands with only N-donor functions were synthesized as well as the Co(II) salt [Co(DHPTBenz)₂](Br_1.7(OH)_0.3) · 4.8H₂O (DHPTBenz = 2,4-bis-(2-diphenylmethylene)-hydrazinyl-6-piperidin-1-yl-1,3,5-triazine). Single crystal X-ray structures of the Co(II) complex, DHPTBenz, and 2,4-dichloro-6-(piperidin-1-yl)-1,3,5-triazine (DCPT) have been determined. The last compound was used as starting material for the tridentate DHPTBenz ligand. Spectroscopic data of the ligand and the starting materials are reported. The Co(II) ion in the complex is distorted octahedrally coordinated by six N atoms of two DHPTBenz ligands. One N atom of the triazine ring of each ligand bonds axially with short distances of 1.953(3) Å and 1.954(3) Å, respectively, whereas two of the hydrazine-N atoms of two ligands form the equatorial plane with an average Co–N bond distance of 2.313 Å. The complex cation has a slightly elongated, nanometer-scaled ball shape with the longest diameter of 1.82 nm.     

Salen型双肟铜(Ⅱ)和钴(Ⅱ)配合物的合成、晶体结构及热性质

一种新的Salen型双肟配体H₂L（H₂L=4,4′-二溴-6,6′-二氯-2,2′-[乙二氧双(氮次甲基)]二酚）分别与一水合乙酸铜或四水合乙酸钴反应,合成了2种配合物即[Cu(L)] (1)和[Co(L)(H₂O)₂]_n (2)。X-射线单晶衍射分析结果表明,配合物1是单核结构,由1个Cu²⁺离子和1个四齿配位的L^2-单元组成。中心Cu^Ⅱ原子的配位数为4,配合物的几何构型为扭曲的四面体。配合物2含有1个Co²⁺离子、1个配体L^2-单元（提供N₂O₂给予体）、2个配位的水分子,其中心Co^Ⅱ原子具有六配位的稍微扭曲的八面体几何构型。该配合物通过分子间氢键和π-π堆积作用形成了线性延伸的金属-水链状超分子结构。     

Structural diversity in the first metal complexes of 2,5-dicarboxamidopyrroles and 2,5-dicarbothioamidopyrroles

Metal complexes of 2,5-dicarboxamidopyrroles and 2,5-dicarbothioamidopyrroles have been structurally characterised for the first time, complementing the significant amount of work that has been reported for the analogous pyridine ligands. N,N'-Bis(3,5-dinitrophenyl)-3,4-diphenyl-1H-pyrrole-2,5-dicarboxamide forms octahedral bis(tridentate) complexes with cobalt(iii) and nickel(ii), where the ligands are bound to the metal centres through deprotonated pyrrole and amide N atoms. N,N'-Dibutyl-3,4-diphenyl-1H-pyrrole-2,5-dicarboxthioamide and N,N'-diphenyl-3,4-diphenyl-1H-pyrrole-2,5-dicarboxthioamide also form bis(tridentate) cobalt complexes but are only deprotonated at the pyrrole N atom, the remainder of the coordination sphere comprising the thioamide S atoms. The dibutyl derivative was isolated as a Co(ii) complex, whereas the diphenyl system deposited a Co(iii) complex. In contrast, N,N'-dibutyl-3,4-dichloro-1H-pyrrole-2,5-dicarboxamide was found to act as a bidentate ligand, in an octahedral cobalt(ii) complex comprising of two bidentate pyrrole ligands, and two aqua ligands. Synthesis of N,N-bis(pyridin-2-ylmethyl)-3,4-diphenyl-1H-pyrrole-2,5-carboxamide gave a pyrrole ligand with increased denticity. Reaction with cobalt(ii) chloride resulted in the isolation of a dinuclear helicate complex. The ligand was found to have undergone addition of a methoxy group to one of the linking methylene carbons, presumably as a result of the oxidative addition of solvent methanol.     

Switching on oxygen activation by cobalt complexes of pentadentate ligands

The monoanionic N(4)O ligand N-methyl-N,N'-bis(2-pyridylmethyl)ethylenediamine-N'-acetate (mebpena(-)) undergoes oxidative C-N bond cleavage in the presence of Co(II) and O(2). The two resultant fragments are coordinated to the metal ion in the product [Co(III)(2-pyridylformate)(mepena)]ClO(4) (mepena(-) = N-methyl-N'-(2-pyridylmethyl)ethylenediamine-N'-acetato). Bond cleavage does not occur in the presence of chloride ions and [Co(III)(mebpena)Cl](+), containing intact mebpena(-), can be isolated. The oxidative instability of the mebpena(-) in the presence of Co(II) and air stands in contrast to the oxidative stability of the family of very closely related penta- and hexa-dentate ligands in their cobalt complexes. Cyclic voltammetry on the matched pair [Co(III)Cl(mebpena)](+) and [Co(II)Cl(bztpen)](+), bztpen = N-benzyl-N,N',N'-tris(2-pyridylmethyl)ethylenediamine, shows that substitution of a pyridine donor for a carboxylato donor results in a relatively small cathodic shift of 150 mV in the E°(Co(II)/Co(III)) oxidation potential, presumably this is enough to determine the contrasting metal oxidation state in the complexes isolated under ambient conditions. DFT calculations support a proposal that [Co(II)(mebpena)](+) reacts with O(2) to form a Co(III)-superoxide complex which can abstract an H atom from a ligand methylene C atom as the initial step towards the observed oxidative C-N bond cleavage.     

Synthesis and characterization studies of 3-formyl chromone Schiff base complexes and their application as antitumor,antioxidant and antimicrobial

A novel Schiff base namely (E)-3-((2,6-dihydroxypyrimidin-4-ylimino)methyl)-4H-chromen-4-one and its Co (II), N (II)i, Cu (II) and Cd (II) complexes have been synthesized and proved by elemental analysis, molar conductance, thermal analysis (TGA), Inductive Coupled plasma (ICP), magnetic moment measurements, X-ray powder diffraction, IR, EI-mass,¹H NMR, ¹³C NMR,UV–Vis. and ESR spectral studies. On the basis of these data, it is evident that the Schiff base acts as bidentate via oxygen atom of carbonyl group and azomethine nitrogen atom for Co (II) complex; monobasic bidentate ligand for Ni (II), Cu (II) and Cd (II) complexes via oxygen atom of hydroxyl group and nitrogen atom of pyrimidine ring. The results showed all complexes have octahedral geometry. The average particle size of the ligand and its complexes were found to be 1.010–0.343 nm. The pharmacological action (antioxidant, antimicrobial and anticancer) of the prepared compounds is studied. The antitumor activity of the ligand and its metal complexes is evaluated against human liver carcinoma (HEPG2) cell. The data displayed the Co (II) complexes strong cytotoxicity where IC₅₀ values of Co (II) complex and 5-fluorouracil (stander drug) are 9.33 and 7.86 μg/ml respectively. The Co (II) and Cd (II) complexes have antibacterial activity more than ampicillin (stander drug). The interaction of the synthesized compounds with calf-thymus DNA (CT-DNA) has been performed via absorption spectra and viscosity technique. The DNA- binding constants have been determined.     

Crystal structures of cobalt(II) complexes with N-(2-hydroxyethyl)iminodiacetic and N,N-bis(2-carbamoylethyl)aminoacetic acids: Co(Heida)·2H2O and Co(Bcegly)(ClO4)·2H2O

The cobalt atom in the structures studied is situated in the center of an octahedron involving donor atoms N and 3O organic ligands Heida or Bcegly (ions of hydroxyethyliminodiacetate or bis(carbamoylethyl)aminoacetate, respectively), water molecule oxygen atom, and a carboxylic atom of the neighboring ligand in the trans-position to the N atom, so that each (II) ion is linked with two organic anions. This results in a formation of infinite chains — uncharged [Co(Heida)(H₂O)]_n or cationic {[Co(Bcegly)(H₂O)]⁺}_n. In both cases, a molecule of crystallization water is present, and in the second case, the charge of the chains is compensated by perchlorate ions. Aminoacetic cycle of the Heida ligand is approximately coplanar to another such cycle, while a similar cycle of the Bcegly ligand is in the plane of one of six-membered aminopropionamide cycles.